Last updated on November 2017

A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old


Brief description of study

A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old

Detailed Study Description

This is a study to assess the pharmacokinetics (PK) of tedizolid phosphate and its active metabolite, tedizolid, and the safety of tedizolid phosphate following administration of a single IV (Part A) or oral suspension (Part B) administration to hospitalized participants ages 6 to <12 years (Groups 1 and 3, respectively), and 2 to <6 years (Groups 2 and 4, respectively).

Clinical Study Identifier: TX9486

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Denise Casey

University of South Florida - Tampa General Hospital
Tampa, FL USA
  Connect »